Clinical Trial Update: Clinical Value of Sequential Gefitinib With Pemetrexed/Platinum for Advanced NSCLC [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/Phase 3 study evaluating sequential gefitinib followed by pemetrexed plus platinum in advanced non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• CISPLATIN (cisplatin)
• Gefitinib (Iressa) (gefitinib)
• Pemetrexed (Alimta) (pemetrexed)

Snippet

Sponsor: Fudan University | Conditions: NSCLC | Phase 2, Phase 3 | Status: COMPLETED